GlassScriptPhysician profile
Andrew Henry Morchower
NPI 1437359213
$14,679.02
in general payments reported to CMS, 2019-2025
63 companies · $2,315 in 2025
The $2,315 reported for 2025 was more than what 81% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,576 · 2020: $3,424 · 2021: $1,887 · 2022: $1,324 · 2023: $1,356 · 2024: $1,798 · 2025: $2,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567 · Travel and Lodging: $814 · Education: $87.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,566.68 |
| Travel and Lodging | $813.70 |
| Education | $87.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,386.89 | 2019-2025 | Eterna, Proclaim |
| Collegium Pharmaceutical, INC. | $1,484.17 | 2019-2025 | Xtampza |
| Vertos Medical, INC. | $1,217.61 | 2019-2022 | |
| Spinal Simplicity, LLC | $1,174.68 | 2022-2025 | Ha Minuteman G3-R |
| Biodelivery Sciences International, INC. | $1,151.65 | 2019-2021 | |
| Nevro Corp. | $771.25 | 2019-2023 | Senza |
| Medtronic, INC. | $583.16 | 2021-2025 | Intellis Adaptivestim, Accurian |
| Merz North America, INC. | $493.99 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.43 | 2020-2025 | Relistor |
| Merz Pharmaceuticals, LLC | $473.59 | 2021-2025 | Xeomin |
| Mdd US Operations, LLC | $396.73 | 2019-2021 | |
| Bioventus LLC | $295.08 | 2019-2022 | |
| Biotronik Nro, INC. | $267.74 | 2024-2025 | Prospera |
| Boston Scientific Corporation | $254.99 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Curonix LLC | $238.39 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $209.92 | 2022-2025 | |
| Daiichi Sankyo INC. | $185.91 | 2019 | |
| Almatica Pharma LLC | $173.41 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $169.19 | 2019-2024 | Ztlido |
| Pfizer INC. | $158.91 | 2019-2025 | |
| Novo Nordisk INC | $120.61 | 2024 | Wegovy |
| Allergan, INC. | $111.09 | 2019-2022 | |
| Stimwave Technologies Incorporated | $108.94 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $104.13 | 2021-2025 | Dysport |
| Acelrx Pharmaceuticals, INC. | $103.27 | 2019 | |
| Foundation Fusion Solutions, LLC | $87.75 | 2023-2024 | |
| Lundbeck LLC | $82.06 | 2022-2024 | Vyepti |
| Itamar Medical INC | $73.70 | 2021-2023 | Watchpatone |
| Assertio Therapeutics, INC. | $73.54 | 2019-2020 | |
| Averitas Pharma INC. | $73.01 | 2024 | Qutenza |
| Protega Pharmaceutials INC | $70.04 | 2025 | Roxybond |
| Painteq LLC | $66.51 | 2024 | Painteq |
| Novartis Pharmaceuticals Corporation | $65.86 | 2019 | |
| Fidia Pharma USA INC. | $61.39 | 2021-2024 | Triluron, Hymovis, Hyalgan |
| Valinor Pharma, LLC | $58.86 | 2024-2025 | Movantik |
| Redhill Biopharma INC. | $56.99 | 2020-2022 | |
| Forte Bio-Pharma LLC | $56.30 | 2020-2022 | |
| Spr Therapeutics, INC | $55.10 | 2023-2025 | Sprint Pns System |
| Avanos Medical | $53.34 | 2023-2024 | Generator, Standard Rf Disposables, Trivisc Sodium Hyaluronate |
| Globus Medical, INC. | $50.60 | 2025 | Senza |
| Pylant Medical | $49.33 | 2024 | |
| Vertical Pharmaceuticals, LLC | $45.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $44.16 | 2021-2022 | |
| Horizon Therapeutics Plc | $38.67 | 2021-2022 | |
| Medtronic USA, INC. | $38.64 | 2019-2020 | |
| Hydrocision, INC. | $36.17 | 2020 | |
| Mml US, INC. | $33.92 | 2023 | Reactiv8 |
| Shionogi INC | $33.08 | 2019 | |
| Depuy Synthes Sales INC. | $32.78 | 2024 | Orthovisc, Monovisc |
| Vertex Pharmaceuticals Incorporated | $31.92 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $25.89 | 2022-2023 | Seglentis |
| Idorsia Pharmaceuticals US INC | $24.04 | 2023 | Quviviq |
| Orthogenrx INC. | $19.93 | 2021 | |
| Djo, LLC | $17.81 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.44 | 2022 | |
| Athena Bioscience, LLC | $16.56 | 2022 | |
| Atland Pharmaceuticals, LLC | $16.37 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Saluda Medical Americas, INC. | $15.94 | 2025 | Evoke |
| Zimmer Biomet Holdings, INC. | $14.45 | 2023 | Gps III Platelet Concentration System |
| Teva Pharmaceuticals USA, INC. | $13.53 | 2020 | |
| Baudax Bio INC. | $12.08 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,167.14 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Morchower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.